Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (trading symbol: OCX) on February 25, 2021. The registrant is incorporated in California and its common stock is listed on the NYSE American. The filing specifically addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity compensation grants rather than financial performance results.
Material Changes and Executive Compensation
On February 25, 2021, the company granted stock options to four executive officers under the Oncocyte 2018 Equity Incentive Plan. The exercise price for all grants was set at $5.34 per share, representing the fair market value of the common stock on the grant date.
| Officer Name | Title | Number of Option Shares |
|---|---|---|
| Ronald Andrews | Chief Executive Officer | 500,000 |
| Mitchell Levine | Chief Financial Officer | 255,000 |
| Douglas Ross | Chief Medical Officer | 255,000 |
| Padmavathi Sundar | Chief Commercial Officer | 255,000 |
Vesting Schedule: 25% of the options vest upon the completion of one year of continuous service. The remaining balance vests in 36 equal monthly installments commencing on the first anniversary of the grant date, subject to continuous employment.
Terms: The options are designated as incentive stock options (ISOs) to the extent permitted by the Internal Revenue Code. They expire ten years from the grant date if not exercised.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements disclaiming any obligation to update such statements. It directs investors to the "Risk Factors" section of the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for additional factors that could cause actual results to differ materially from anticipated results. No specific operational guidance or new risk contingencies were disclosed in this document.
Investor Verification Checklist
- Verify the current share price relative to the $5.34 exercise price to assess the intrinsic value of the grants.
- Review the Oncocyte 2018 Equity Incentive Plan to confirm the total pool of shares available for future grants.
- Check the company's most recent Form 10-K or 10-Q for updated financial performance metrics, as this 8-K does not contain them.
- Monitor the vesting schedule to understand the timeline for potential dilution from these specific grants.